JPRN-UMIN000007042CompletedPhase 4
Efficacy and Adherence of Xalacom Combination Therapy in Glaucoma Patients Switching from a Multi-Drug Therapy (PG and beta blocker medication) - Efficacy and Adherence of Xalacom switching from a Multi-Drug Therapy
Department of Ophthalmology, Kitasato University Hospital0 sites50 target enrollmentStarted: January 10, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patients in whom the studied drug is "Contraindication" 2) Patients in whom the studied drug is "Careful Administration" 3) Patients with corneal abnormalities that would hinder the measurement of IOP using Goldmann applanation tonometry 4) Patients whose pupils could dilate so insufficiently that it is impossible to observe optic papillae 5) Patients with a history of a laser treatment 6) Patients with uveititis, an eye injury, an infectious eye disease or an inflammatory eye disease as an accompanying disease 7) Patients with a history of narrow angle that may be closed, or acute angle closure 8) Patients with a retinal disease that might affect the visual field of either or both eyes, as an accompanying disease 9) Patients with a history of an infectious disease within four weeks of participation in this study 10) Patients who had been using any drug that might have a systemic effect that affects intraocular pressure 11) Patients assessed as unsuitable for participation in the study by the investigator and/or subinvestigators
Investigators
Similar Trials
Unknown
Phase 1
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsFirst-line TreatmentAdvanced Gastric CarcinomaNCT05221775Tianjin Medical University Cancer Institute and Hospital18
Completed
Phase 3
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular HypertensionGlaucoma, Open AngleOcular HypertensionNCT00219596Pfizer's Upjohn has merged with Mylan to form Viatris Inc.240
Completed
Not Applicable
Long Term Use Of Xalacom In Patients Glaucoma Or Ocular HypertensionGlaucomaOcular HypertensionNCT01191008Pfizer's Upjohn has merged with Mylan to form Viatris Inc.661
Completed
Phase 4
Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancerColorectal CancerJPRN-UMIN000003915Kyushu Study group of Clinical Cancer41
Suspended
Phase 2
Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric CancerGastric CancerNCT00568529Fudan University30
